1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Cell Impact reports smaller quarterly loss, revenue sharply down
Cell Impact reports a loss of SEK 0.19 per share for the quarter ended 31 Dec 2025 (previous year: -0.35 SEK) on revenue of SEK 1.1m, a decline of 50.9% from SEK 2.2m. For the full year, loss per share fell to SEK 0.65 (previous year: -0.92 SEK), and annual revenue fell to SEK 5.57m, down 85.1% from SEK 37.33m in the previous year. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 129.13k | 32,16% |
| Gross profit | −1.56m | 2.149,44% |
| Net profit | −1.59m | 16,42% |
| EBITDA | −1.00m | 9,88% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 1.43m€ |
Number of shares | 293.49m |
52-week high/low | 0,0577€ - 0,00478€ |
| Dividends | No |
Beta | 1,84 |
P/E ratio | −0,13 |
PEG ratio | 0,00 |
P/B ratio | 0,30 |
P/S ratio | 3,11 |
Company profile
| Name | Cell Impact AB |
| CEO | Daniel Vallin |
| Employees | 25 |
Discover assets
Shareholders of Cell Impact AB also invest in the following assets
